EIGR
- Eiger BioPharmaceuticals, Inc.
()
Overview
Company Summary
Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases. The company's primary objective is to address areas of urgent unmet medical need, where there are limited or no treatment options available.
Eiger BioPharmaceuticals has a diverse pipeline of product candidates that encompass both small molecule drugs and antibody-based therapies. These candidates are designed to target specific pathways in the body that are implicated in various diseases, with the aim of providing effective and safe treatment options.
The company's research and development efforts are primarily focused on diseases such as hepatitis delta virus (HDV) infection, autoimmune and fibrotic diseases, and pulmonary arterial hypertension (PAH). HDV is a severe liver disease caused by infection with the hepatitis delta virus, for which there are currently no approved therapies. Eiger's lead candidate, Lonafarnib, is being evaluated for the treatment of HDV and has shown promising results in clinical trials.
Additionally, Eiger BioPharmaceuticals is developing potential treatments for autoimmune and fibrotic diseases, including lymphedema, systemic scleroderma, and orphan fibrotic conditions. These diseases involve abnormal immune responses or excessive tissue scarring, both of which can lead to severe symptoms and organ damage.
The company's strategic focus also extends to pulmonary arterial hypertension (PAH), a progressive and life-threatening disease characterized by high blood pressure in the arteries of the lungs. Eiger is investigating a potential therapy called Avexitide, which targets a specific hormone receptor involved in PAH.
In summary, Eiger BioPharmaceuticals is a biopharmaceutical company specialized in developing targeted therapies for rare and ultra-rare diseases with limited or no treatment options. By focusing on areas of high unmet medical need, the company aims to provide innovative solutions and improve the lives of patients affected by these severe conditions.